Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJOncoAlert Journal Club | Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer

Erika Hamilton • 11 Jun 2025
VJOncoAlert Journal Club
Breast Cancer Fulvestrant Vepdegestrant
VERITAC-2

In this latest episode of the VJOncoAlert Journal Club, Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, discusses the findings of the VERITAC-2 trial (NCT05654623), a Phase III, open-labeled, randomized trial evaluating vepdegestrant, an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader, in patients with ER-positive, HER2-negative advanced breast cancer, as published in the New England Journal of Medicine (NEJM). In the VERITAC-2 trial, vepdegestrant significantly improved progression-free survival versus fulvestrant in ESR1-mutated advanced breast cancer patients previously treated with endocrine therapy and CDK4/6 inhibitors.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Erika Hamilton

Breast cancer updates at ASCO 2026: KEYNOTE-522, SERENA-6, and more
1:50
Breast cancer updates at ASCO 2026: KEYNOTE-522, SERENA-6, and more
Erika Hamilton • 5 Jun 2026
Optimizing sequencing & maintenance strategies in HER2+ metastatic breast cancer
2:21
Optimizing sequencing & maintenance strategies in HER2+ metastatic breast cancer
Erika Hamilton • 5 Jun 2026
HER2CLIMB-05: subgroup analyses of tucatinib, trastuzumab & pertuzumab in HER2+ mBC
4:01
HER2CLIMB-05: subgroup analyses of tucatinib, trastuzumab & pertuzumab in HER2+ mBC
Erika Hamilton • 5 Jun 2026
Sequencing HER2+ therapies in breast cancer: insights on ADCs, TKIs, chemo, & maintenance strategies
1:25
Sequencing HER2+ therapies in breast cancer: insights on ADCs, TKIs, chemo, & maintenance strategies
Erika Hamilton • 10 Dec 2025

Related Videos

HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
1:15
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
Sanjoy Chatterjee • 17 May 2026
Adherence to weight loss intervention in breast cancer patients
1:09
Adherence to weight loss intervention in breast cancer patients
Jennifer Ligibel • 31 May 2026
The content of VJOncology is intended for healthcare professionals